نتائج البحث

1

BAI1 nuclear expression reflects the survival of nonsmoking non‐small cell lung cancer patients

المؤلفون: Dae Hyun Song, Hye Jin Baek, Jung Wook Yang, Kyeong Hwa Ryu, Min Hye Kim, Jun Young Choi, Kyung Nyeo Jeon, Chang Sup Lee, Hyo Jung An, Sung Hwan Kim

المصدر: Thoracic Cancer, Vol 12, Iss 11, Pp 1673-1680 (2021)
Thoracic Cancer

مصطلحات موضوعية: 0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, Adult, Male, non‐small cell lung cancer, medicine.medical_specialty, Lung Neoplasms, medicine.disease_cause, Receptors, G-Protein-Coupled, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Carcinoma, Non-Small-Cell Lung, Medicine, Humans, Angiogenic Proteins, Lung cancer, Survival analysis, RC254-282, Aged, Lung, Predictive marker, Tissue microarray, business.industry, Hazard ratio, Smoking, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, General Medicine, Original Articles, Middle Aged, medicine.disease, Prognosis, Survival Analysis, respiratory tract diseases, 030104 developmental biology, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Cancer cell, Original Article, Female, nonsmoking, business, Carcinogenesis, brain‐specific angiogenesis inhibitor 1

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e72075b1d77162dce13b2dca6cecbf94Test
https://doaj.org/article/d57ace13361e42f5b9bdf3d966606dc3Test

2

Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non‐small cell lung cancer treated with anti‐PD ‐1 antibody

المؤلفون: Yuji Matsumoto, Yuichiro Ohe, Hidehito Horinouchi, Ryota Shibaki, Shuji Murakami, Noboru Yamamoto, Yasushi Goto, Shintaro Kanda, Yutaka Fujiwara, Tatsuya Yoshida

المصدر: Thoracic Cancer

مصطلحات موضوعية: non‐small cell lung cancer, Adult, Male, 0301 basic medicine, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Lung Neoplasms, Multivariate analysis, soluble PD‐L1, Pembrolizumab, Antibodies, Monoclonal, Humanized, Gastroenterology, Programmed cell death ligand 1, 03 medical and health sciences, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Internal medicine, mental disorders, medicine, Humans, Anti‐PD‐1 antibody, In patient, Lung cancer, Aged, Aged, 80 and over, biology, business.industry, Hazard ratio, Original Articles, General Medicine, PD‐L1 TPS, Middle Aged, Prognosis, medicine.disease, Survival Analysis, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, biology.protein, Original Article, Female, Nivolumab, Antibody, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19fced2ae8c7ae9ecc4e68e52a492d5dTest
https://doi.org/10.1111/1759-7714.13721Test

3

Poor efficacy of anti‐programmed cell death‐1/ligand 1 monotherapy for non‐small cell lung cancer patients with active brain metastases

المؤلفون: Tsukasa Hasegawa, Ryo Ariyasu, Masahiro Seike, Makoto Nishio, Takeshi Horai, Hiroshi Yoshida, Noriko Yanagitani, Akihiko Gemma, Ken Uchibori, Takehiro Tozuka, Satoru Kitazono, Yoshiaki Amino, Takahiro Yoshizawa, Hiroaki Sakamoto, Shinya Uematsu

المصدر: Thoracic Cancer
Thoracic Cancer, Vol 11, Iss 9, Pp 2465-2472 (2020)

مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Lung Neoplasms, medicine.medical_treatment, immune checkpoint inhibitor, B7-H1 Antigen, central nervous system metastases, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, brain metastases, Programmed cell death 1, Medicine, Aged, 80 and over, biology, Brain Neoplasms, digestive, oral, and skin physiology, General Medicine, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 030220 oncology & carcinogenesis, Female, Original Article, Non small cell, medicine.symptom, Antibody, Adult, Pulmonary and Respiratory Medicine, medicine.medical_specialty, education, lcsh:RC254-282, Anti PD‐1/PD‐L1 antibody, Asymptomatic, 03 medical and health sciences, Internal medicine, Humans, Poor performance status, Lung cancer, Aged, Retrospective Studies, business.industry, Retrospective cohort study, Original Articles, Immunotherapy, medicine.disease, stomatognathic diseases, 030104 developmental biology, biology.protein, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8f1ff75d1a1081b9e457351f91678f9Test
https://doi.org/10.1111/1759-7714.13557Test

4

Utility of CT radiomics for prediction of PD‐L1 expression in advanced lung adenocarcinomas

المؤلفون: Hye Jeong Lee, Jiyoung Yoon, Kyunghwa Han, Byoung Wook Choi, Hyoun Cho, Jin Hur, Young-Joo Suh

المصدر: Thoracic Cancer, Vol 11, Iss 4, Pp 993-1004 (2020)
Thoracic Cancer

مصطلحات موضوعية: 0301 basic medicine, Pulmonary and Respiratory Medicine, Adult, Male, medicine.medical_specialty, Lung Neoplasms, Computed tomography, Adenocarcinoma of Lung, Logistic regression, lcsh:RC254-282, B7-H1 Antigen, 03 medical and health sciences, 0302 clinical medicine, Radiomics, Statistical significance, medicine, Humans, Aged, Neoplasm Staging, Retrospective Studies, Aged, 80 and over, Lung, medicine.diagnostic_test, Receiver operating characteristic, business.industry, Retrospective cohort study, General Medicine, Original Articles, Middle Aged, medicine.disease, lung adenocarcinoma, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 030104 developmental biology, medicine.anatomical_structure, Oncology, ROC Curve, programmed death ligand 1, radiomics, 030220 oncology & carcinogenesis, Adenocarcinoma, Original Article, Female, Radiology, immunotherapy, business, Tomography, X-Ray Computed, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbe18dec001e3f8bc57cee2272b5e016Test
https://doaj.org/article/c5fdbf4615b74772bebdbcb6184c03f2Test

5

Patterns of response in metastatic NSCLC during PD‐1 or PD‐L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria

المؤلفون: Mengzhao Wang, Yan Xu, Minjiang Chen, Wei Zhong, Hongge Liang, Jing Zhao

المصدر: Thoracic Cancer, Vol 11, Iss 4, Pp 1068-1075 (2020)
Thoracic Cancer

مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Lung Neoplasms, medicine.medical_treatment, Programmed Cell Death 1 Receptor, pseudoprogression, B7-H1 Antigen, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Retrospective analysis, Immune Checkpoint Inhibitors, iRECIST, Hazard ratio, General Medicine, Middle Aged, Prognosis, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Survival Rate, 030220 oncology & carcinogenesis, Carcinoma, Squamous Cell, Female, Original Article, Immunotherapy, Adult, Pulmonary and Respiratory Medicine, non‐small cell lung cancer, medicine.medical_specialty, Adenocarcinoma of Lung, RECIST 1.1, lcsh:RC254-282, 03 medical and health sciences, Internal medicine, medicine, Humans, Pathological, Pseudoprogression, Response Evaluation Criteria in Solid Tumors, Aged, Retrospective Studies, business.industry, Original Articles, medicine.disease, Confidence interval, 030104 developmental biology, PD-L1 inhibitor, business, Progressive disease, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23321619ea032a106f303ea577065093Test
https://doaj.org/article/ab6ba9e8aa174f2797bc4f0bb4bdb67bTest

6

Comparisons between tumor burden and other prognostic factors that influence survival of patients with non‐small cell lung cancer treated with immune checkpoint inhibitors

المؤلفون: Tatsuya Nitawaki, Takuro Sakagami, Naoki Shingu, Yuko Sekido, Yuko Yasuda, Aiko Nakano, Kodai Kawamura, Yoshihiko Sakata, Yoshitomo Eguchi, Jumpei Hisanaga, Kazuya Ichikado, Miwa Iio

المصدر: Thoracic Cancer, Vol 10, Iss 12, Pp 2259-2266 (2019)
Thoracic Cancer

مصطلحات موضوعية: Adult, Male, non‐small cell lung cancer, 0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Prognostic factor, Lung Neoplasms, Immune checkpoint inhibitors, Tumor burden, Immune checkpoint inhibitor, lcsh:RC254-282, Programmed cell death ligand 1, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Internal medicine, Biomarkers, Tumor, medicine, Humans, Molecular Targeted Therapy, prognostic biomarker, Lung cancer, Aged, Neoplasm Staging, Proportional Hazards Models, Aged, 80 and over, Receiver operating characteristic, business.industry, Proportional hazards model, Original Articles, General Medicine, Middle Aged, Prognosis, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Treatment Outcome, 030104 developmental biology, 030220 oncology & carcinogenesis, Original Article, Female, Non small cell, business, tumor burden

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20055af3f9dbba302975d5fe1162123fTest
https://doi.org/10.1111/1759-7714.13214Test

7

Molecular characterization of clinical responses to PD‐1/PD‐L1 inhibitors in non‐small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD‐1 inhibitors in Chinese patients

المؤلفون: Kai Wang, Xiangdong Zhou, Qi Wang, Xiaoxia Cui, Xiaoyu Zhang, Chunxue Bai, Li Zhang, Jian Zhang, Jianping Zhao, Peng Song, Xiaoju Zhang, Faguang Jin, Yao Yu, Li Bai, Xiaoli Zhu, Yanbin Zhou, Chengzhi Zhou

المصدر: Thoracic Cancer

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Lung Neoplasms, Adolescent, medicine.medical_treatment, Programmed Cell Death 1 Receptor, Pembrolizumab, NSCLC, Multi‐omics, B7-H1 Antigen, Young Adult, Study Protocol, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, PD‐1/PD‐L1 inhibitor, Carcinoma, Non-Small-Cell Lung, PD-L1, Internal medicine, Biomarkers, Tumor, medicine, Humans, Molecular Targeted Therapy, predictive biomarker, Lung cancer, Aged, Response rate (survey), biology, business.industry, General Medicine, Immunotherapy, Middle Aged, medicine.disease, Clinical trial, Treatment Outcome, 030104 developmental biology, 030220 oncology & carcinogenesis, biology.protein, Immunohistochemistry, Female, Nivolumab, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adb9f8018da18f4739ee639337e1c7efTest
https://doi.org/10.1111/1759-7714.13078Test

8

Clinical significance of ≥ 50% PD‐L1 expression with the SP263 monoclonal antibody in non‐small cell lung cancer patients

المؤلفون: Changyuan Guo, Peng Song, Lei Guo, Xiuyun Liu, Shugeng Gao, Wenbin Li, Jianming Ying

المصدر: Thoracic Cancer
Thoracic Cancer, Vol 10, Iss 2, Pp 175-182 (2019)

مصطلحات موضوعية: 0301 basic medicine, Male, Lung Neoplasms, Gastroenterology, B7-H1 Antigen, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Incidence (epidemiology), Antibodies, Monoclonal, General Medicine, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Prognosis, ErbB Receptors, Survival Rate, Oncology, 030220 oncology & carcinogenesis, Carcinoma, Squamous Cell, Pd l1 expression, Original Article, Female, Non small cell, Pulmonary and Respiratory Medicine, non‐small cell lung cancer, Adult, medicine.medical_specialty, medicine.drug_class, Adenocarcinoma of Lung, Monoclonal antibody, lcsh:RC254-282, smoking, 03 medical and health sciences, Internal medicine, medicine, Biomarkers, Tumor, Humans, In patient, Clinical significance, Lung cancer, Aged, Retrospective Studies, business.industry, Driver mutation, Original Articles, medicine.disease, 030104 developmental biology, programmed death ligand 1, Mutation, business, Immunostaining, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0da44542a2adec12ac5f84b70fd22f0Test
http://europepmc.org/articles/PMC6360219Test

9

Real-world efficacy of atezolizumab in non-small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody

المؤلفون: Kazushige Wakuda, Satoshi Ikeda, Masafumi Sata, Ryota Ushio, Kentaro Ito, Takashi Sato, Shigeru Tanzawa, Naoki Furuya, Makoto Nishino

المصدر: Thoracic Cancer
Thoracic Cancer, Vol 12, Iss 5, Pp 613-618 (2021)

مصطلحات موضوعية: 0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, Adult, Male, atezolizumab, non‐small cell lung cancer, medicine.medical_specialty, Lung Neoplasms, Pembrolizumab, Antibodies, Monoclonal, Humanized, lcsh:RC254-282, Cohort Studies, 03 medical and health sciences, anti‐PD‐L1, 0302 clinical medicine, Atezolizumab, Internal medicine, Carcinoma, Non-Small-Cell Lung, medicine, Humans, Lung cancer, Immune Checkpoint Inhibitors, Aged, Retrospective Studies, Aged, 80 and over, Performance status, business.industry, Anti pd 1, General Medicine, Original Articles, Middle Aged, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Confidence interval, 030104 developmental biology, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Retreatment, Female, Original Article, Nivolumab, business, Cohort study

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12194075aa42c60389387090977b3ce3Test
https://pubmed.ncbi.nlm.nih.gov/33448648Test

10

PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1

المؤلفون: Jongmin, Lee, Chan Kwon, Park, Hyoung-Kyu, Yoon, Young Jo, Sa, In Sook, Woo, Hyo Rim, Kim, Sue Youn, Kim, Tae-Jung, Kim

المصدر: Thoracic Cancer

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=pmid________::02eb8e7a24c94dc7ecdd8f4bdbfe6098Test
https://pubmed.ncbi.nlm.nih.gov/30475455Test

تنقيح النتائج